CABASTINE

Details

Stereochemistry	RACEMIC
Molecular Formula	C26H29FN2O2
Molecular Weight	420.5191
Optical Activity	( + / - )
Defined Stereocenters	4 / 4
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

C[C@@H]1CN(CC[C@]1(C(O)=O)C2=CC=CC=C2)[C@H]3CC[C@](CC3)(C#N)C4=CC=C(F)C=C4

InChI

InChIKey=ZCGOMHNNNFPNMX-KYTRFIICSA-N

InChI=1S/C26H29FN2O2/c1-19-17-29(16-15-26(19,24(30)31)21-5-3-2-4-6-21)23-11-13-25(18-28,14-12-23)20-7-9-22(27)10-8-20/h2-10,19,23H,11-17H2,1H3,(H,30,31)/t19-,23-,25-,26-/m1/s1

HIDE SMILES / InChI

Molecular Formula	C26H29FN2O2
Molecular Weight	420.5191
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	4 / 4
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=420b3f66-87f0-47d8-947c-541e84eb594a
Curator's Comment: description was created based on several sources, including http://www.rxlist.com/livostin-side-effects-drug-center.htm

Levocabastine (trade name Livo) is a selective second-generation H1-receptor antagonist used for allergic conjunctivitis. Levocabastine binds the G protein-coupled neurotensin receptor 2 (NTR2), but not NTR1, where it behaves as a weak partial inverse agonist. In an environmental study, LIVOSTIN 0.05% (levocabastine hydrochloride ophthalmic suspension) instilled four times daily was shown to be significantly more effective than its vehicle in reducing ocular itching associated with seasonal allergic conjunctivitis. After instillation in the eye, levocabastine is systemically absorbed. However, the amount of systemically absorbed levocabastine after therapeutic ocular doses is low (mean plasma concentrations in the range of 1-2 ng/mL). Brand name Livostin is no longer available in the U.S., but generic versions may still be available. Common side effects include burning, stinging, itching, or watering of the eyes, eye irritation or discomfort, blurred vision, dry or puffy eyes, headache, nosebleed, nausea, or fatigue.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Histamine H1 receptor 316 Target ID: CHEMBL231 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11915520	Antagonist 2849
Neurotensin receptor type 2 3 Target ID: O95665 Gene ID: 23620.0 Gene Symbol: NTSR2 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/8647296	Inverse Agonist 85

Conditions

Condition	Modality	Targets	Highest Phase	Product
Seasonal allergic conjunctivitis 3 Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=420b3f66-87f0-47d8-947c-541e84eb594a	Palliative		Approved 8583	LIVOSTIN Approved Use LIVOSTIN™ 0.05% (levocabastine hydrochloride ophthalmic suspension) is indicated for the temporary relief of the signs and symptoms of seasonal allergic conjunctivitis. Launch Date 1993

C_max

Value	Dose	Analyte	Population
7.4 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7907347/	0.5 mg single, oral dose: 0.5 mg route of administration: Oral experiment type: SINGLE co-administered:	LEVOCABASTINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
7.3 μg/L REVIEW https://pubmed.ncbi.nlm.nih.gov/8549024/	0.5 mg single, oral dose: 0.5 mg route of administration: Oral experiment type: SINGLE co-administered:	LEVOCABASTINE plasma	Homo sapiens population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
12.1 μg/L REVIEW https://pubmed.ncbi.nlm.nih.gov/8549024/	1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered:	LEVOCABASTINE plasma	Homo sapiens population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
22.2 μg/L REVIEW https://pubmed.ncbi.nlm.nih.gov/8549024/	2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered:	LEVOCABASTINE plasma	Homo sapiens population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
319 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7907347/	0.5 mg single, oral dose: 0.5 mg route of administration: Oral experiment type: SINGLE co-administered:	LEVOCABASTINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
337 μg × h/L REVIEW https://pubmed.ncbi.nlm.nih.gov/8549024/	0.5 mg single, oral dose: 0.5 mg route of administration: Oral experiment type: SINGLE co-administered:	LEVOCABASTINE plasma	Homo sapiens population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
580 μg × h/L REVIEW https://pubmed.ncbi.nlm.nih.gov/8549024/	1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered:	LEVOCABASTINE plasma	Homo sapiens population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
1142 μg × h/L REVIEW https://pubmed.ncbi.nlm.nih.gov/8549024/	2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered:	LEVOCABASTINE plasma	Homo sapiens population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
35.7 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7907347/	0.5 mg single, oral dose: 0.5 mg route of administration: Oral experiment type: SINGLE co-administered:	LEVOCABASTINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
37.5 h REVIEW https://pubmed.ncbi.nlm.nih.gov/8549024/	0.5 mg single, oral dose: 0.5 mg route of administration: Oral experiment type: SINGLE co-administered:	LEVOCABASTINE plasma	Homo sapiens population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
37.5 h REVIEW https://pubmed.ncbi.nlm.nih.gov/8549024/	1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered:	LEVOCABASTINE plasma	Homo sapiens population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

F_unbound

Value	Dose	Analyte	Population
45% REVIEW https://pubmed.ncbi.nlm.nih.gov/8549024/	0.5 mg single, oral dose: 0.5 mg route of administration: Oral experiment type: SINGLE co-administered:	LEVOCABASTINE plasma	Homo sapiens population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
45% REVIEW https://pubmed.ncbi.nlm.nih.gov/8549024/	1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered:	LEVOCABASTINE plasma	Homo sapiens population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
45% REVIEW https://pubmed.ncbi.nlm.nih.gov/8549024/	2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered:	LEVOCABASTINE plasma	Homo sapiens population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
0.05 % 4 times / day multiple, ophthalmic Recommended Dose: 0.05 %, 4 times / day Route: ophthalmic Route: multiple Dose: 0.05 %, 4 times / day Sources: https://db.cbg-meb.nl/veegactie/csp/Levocabastine_okt2014.pdf	unhealthy, 5 - 17 years Health Status: unhealthy Age Group: 5 - 17 years Sex: M+F Sources: https://db.cbg-meb.nl/veegactie/csp/Levocabastine_okt2014.pdf	Disc. AE: Headache, Blepharoconjunctivitis... AEs leading to discontinuation/dose reduction: Headache (3 patients) Blepharoconjunctivitis (3 patients) Sources: https://db.cbg-meb.nl/veegactie/csp/Levocabastine_okt2014.pdf
0.5 mg/mL 2 times / day multiple, ophthalmic Recommended Dose: 0.5 mg/mL, 2 times / day Route: ophthalmic Route: multiple Dose: 0.5 mg/mL, 2 times / day Sources: https://www.researchgate.net/publication/5375238_Levocabastine_eye_drops_are_effective_and_well_tolerated_for_the_treatment_of_allergic_conjunctivitis_in_children	unhealthy, < 12 years Health Status: unhealthy Age Group: < 12 years Sex: M+F Sources: https://www.researchgate.net/publication/5375238_Levocabastine_eye_drops_are_effective_and_well_tolerated_for_the_treatment_of_allergic_conjunctivitis_in_children	Other AEs: Eye disorders NEC... Other AEs: Eye disorders NEC (33 patients) Sources: https://www.researchgate.net/publication/5375238_Levocabastine_eye_drops_are_effective_and_well_tolerated_for_the_treatment_of_allergic_conjunctivitis_in_children
0.5 mg/mL 2 times / day multiple, ophthalmic Recommended Dose: 0.5 mg/mL, 2 times / day Route: ophthalmic Route: multiple Dose: 0.5 mg/mL, 2 times / day Sources: https://www.researchgate.net/publication/5375238_Levocabastine_eye_drops_are_effective_and_well_tolerated_for_the_treatment_of_allergic_conjunctivitis_in_children	unhealthy, > 12 years Health Status: unhealthy Age Group: > 12 years Sex: M+F Sources: https://www.researchgate.net/publication/5375238_Levocabastine_eye_drops_are_effective_and_well_tolerated_for_the_treatment_of_allergic_conjunctivitis_in_children	Other AEs: Eye disorders NEC... Other AEs: Eye disorders NEC (7 patients) Sources: https://www.researchgate.net/publication/5375238_Levocabastine_eye_drops_are_effective_and_well_tolerated_for_the_treatment_of_allergic_conjunctivitis_in_children
0.05 % 4 times / day multiple, ophthalmic Recommended Dose: 0.05 %, 4 times / day Route: ophthalmic Route: multiple Dose: 0.05 %, 4 times / day Sources: https://db.cbg-meb.nl/veegactie/csp/Levocabastine_okt2014.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: unknown Sources: https://db.cbg-meb.nl/veegactie/csp/Levocabastine_okt2014.pdf	Disc. AE: Eye disorders NEC... AEs leading to discontinuation/dose reduction: Eye disorders NEC (23 patients) Sources: https://db.cbg-meb.nl/veegactie/csp/Levocabastine_okt2014.pdf
0.2 mg/mL 2 times / day multiple, intranasal Recommended Dose: 0.2 mg/mL, 2 times / day Route: intranasal Route: multiple Dose: 0.2 mg/mL, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/10088031/	unhealthy, mean 38.8 years Health Status: unhealthy Age Group: mean 38.8 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/10088031/	Sources: https://pubmed.ncbi.nlm.nih.gov/10088031/

AEs

AE	Significance	Dose	Population
Blepharoconjunctivitis	3 patients Disc. AE	0.05 % 4 times / day multiple, ophthalmic Recommended Dose: 0.05 %, 4 times / day Route: ophthalmic Route: multiple Dose: 0.05 %, 4 times / day Sources: https://db.cbg-meb.nl/veegactie/csp/Levocabastine_okt2014.pdf	unhealthy, 5 - 17 years Health Status: unhealthy Age Group: 5 - 17 years Sex: M+F Sources: https://db.cbg-meb.nl/veegactie/csp/Levocabastine_okt2014.pdf
Headache	3 patients Disc. AE	0.05 % 4 times / day multiple, ophthalmic Recommended Dose: 0.05 %, 4 times / day Route: ophthalmic Route: multiple Dose: 0.05 %, 4 times / day Sources: https://db.cbg-meb.nl/veegactie/csp/Levocabastine_okt2014.pdf	unhealthy, 5 - 17 years Health Status: unhealthy Age Group: 5 - 17 years Sex: M+F Sources: https://db.cbg-meb.nl/veegactie/csp/Levocabastine_okt2014.pdf
Eye disorders NEC	33 patients	0.5 mg/mL 2 times / day multiple, ophthalmic Recommended Dose: 0.5 mg/mL, 2 times / day Route: ophthalmic Route: multiple Dose: 0.5 mg/mL, 2 times / day Sources: https://www.researchgate.net/publication/5375238_Levocabastine_eye_drops_are_effective_and_well_tolerated_for_the_treatment_of_allergic_conjunctivitis_in_children	unhealthy, < 12 years Health Status: unhealthy Age Group: < 12 years Sex: M+F Sources: https://www.researchgate.net/publication/5375238_Levocabastine_eye_drops_are_effective_and_well_tolerated_for_the_treatment_of_allergic_conjunctivitis_in_children
Eye disorders NEC	7 patients	0.5 mg/mL 2 times / day multiple, ophthalmic Recommended Dose: 0.5 mg/mL, 2 times / day Route: ophthalmic Route: multiple Dose: 0.5 mg/mL, 2 times / day Sources: https://www.researchgate.net/publication/5375238_Levocabastine_eye_drops_are_effective_and_well_tolerated_for_the_treatment_of_allergic_conjunctivitis_in_children	unhealthy, > 12 years Health Status: unhealthy Age Group: > 12 years Sex: M+F Sources: https://www.researchgate.net/publication/5375238_Levocabastine_eye_drops_are_effective_and_well_tolerated_for_the_treatment_of_allergic_conjunctivitis_in_children
Eye disorders NEC	23 patients Disc. AE	0.05 % 4 times / day multiple, ophthalmic Recommended Dose: 0.05 %, 4 times / day Route: ophthalmic Route: multiple Dose: 0.05 %, 4 times / day Sources: https://db.cbg-meb.nl/veegactie/csp/Levocabastine_okt2014.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: unknown Sources: https://db.cbg-meb.nl/veegactie/csp/Levocabastine_okt2014.pdf

Overview

CYP3A4	CYP2C9	CYP2D6	hERG

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP 450 20	CYP 450 32

Drug as perpetrator

Target	Modality	Activity	Metabolite	Clinical evidence
CYP 450 22	inhibitor 4027 Sources: https://accp1.onlinelibrary.wiley.com/doi/abs/10.1177/00912709922007589 Page: 1.0	no		unlikely (co-administration study) Comment: the likelihood of systemic drug interactions with drugs affecting the cytochrome P-450 is minimal Sources: https://accp1.onlinelibrary.wiley.com/doi/abs/10.1177/00912709922007589 Page: 1.0

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
CYP 450 32	substrate 4014 Sources: https://accp1.onlinelibrary.wiley.com/doi/abs/10.1177/00912709922007589 Page: 1.0	no		unlikely (co-administration study) Comment: the likelihood of systemic drug interactions with drugs affecting the cytochrome P-450 is minimal Sources: https://accp1.onlinelibrary.wiley.com/doi/abs/10.1177/00912709922007589 Page: 1.0

Sourcing

Vendor/Aggregator	ID	URL
1PlusChem LLC	1P0058MI
ABI Chem	AC1L1GWR
Achemtek	0102-012957	http://www.achemtek.com/79516-68-0
Alfa Chemistry	80185-65-5
AN PharmaTech	AN-6364
BePharm Ltd.	B136220
BOC Sciences	80185-65-5
Chemieliva Pharmaceutical Co., Ltd	PBCM0841436
ChemMol	49401013	http://www.chemmol.com/chemmol/49401013.html
Clearsynth	CS-AD-00421	http://www.clearsynth.com/en/CSAD00421.html
Compound Cloud	54384
Compound Cloud	54385
eNovation Chemicals	D674472	https://www.enovationchem.com/ProductDetails.asp?ProductID=D674472
Hairui	HR139897
Nanjing Pope Bio-tech	NSTH-D02017
Norris Pharm	NSTH-D02017
NovoSeek	54385
Oxchem Corporation	AX8136220
Smolecule	S532933	http://www.smolecule.com/products/s532933
THE BioTek	bt-273330	https://www.thebiotek.com/product/inhibitors/bt-273330
THE BioTek	bt-404790	https://www.thebiotek.com/product/others/bt-404790
W&J PharmaChem	100424
ZINC	ZINC000000586239	http://zinc15.docking.org/substances/ZINC000000586239

PubMed

Title	Date	PubMed
Spinal NTS2 receptor activation reverses signs of neuropathic pain.	2013-09	23756650
Evaluation of histamine-induced conjunctival oedema in guinea pigs by means of image analysis.	2010-12	20956272
Clinical utility and patient adherence with ebastine for allergic rhinitis.	2010-10-14	21206514
Neurotensin is a regulator of insulin secretion in pancreatic beta-cells.	2010-10	20601081
Azelastine hydrochloride, a dual-acting anti-inflammatory ophthalmic solution, for treatment of allergic conjunctivitis.	2010-09-07	20856595
Levocabastine nasal spray significantly improves perennial allergic rhinitis: a single-blind placebo-controlled study.	2010-08	20138720
Relation between cooling sheet effect and tear histamine concenration in allergic conjunctivitis.	2010-07	20606377
Bepotastine besilate, a highly selective histamine H(1) receptor antagonist, suppresses vascular hyperpermeability and eosinophil recruitment in in vitro and in vivo experimental allergic conjunctivitis models.	2010-07	20412793
Treatment of allergic conjunctivitis: results of a 1-month, single-masked randomized study.	2010-04-13	20383847
Treatment of congestion in upper respiratory diseases.	2010-04-08	20463825
beta-Lactotensin derived from bovine beta-lactoglobulin suppresses food intake via the CRF system followed by the CGRP system in mice.	2009-12	19720102
Azelastine nasal spray for the treatment of allergic and nonallergic rhinitis.	2009-11	20477689
NT69L, a novel analgesic, shows synergy with morphine.	2009-10-19	19651107
[Effect of intra nasally applied fluticasone propionate and levocabastine on the expression of aquaporin 5 in nasal mucosa of rat with experimental allergic rhinitis].	2009-10	20128285
Evidence for a role of NTS2 receptors in the modulation of tonic pain sensitivity.	2009-07-06	19580660
Role of histamine H(4) receptor in allergic conjunctivitis in mice.	2009-04-17	19249296
The effect of levocabastine hydrochloride on human Tenon's capsule fibroblasts: inhibition of proliferation, suppression of DNA synthesis and induction of apoptosis.	2009	19473114
[Intra-annual and seasonal allergic conjunctivitis treatment: comparison of two therapeutic protocols].	2008-12	19107071
Drug use in children: cohort study in three European countries.	2008-11-24	19029175
Randomized double-blind placebo-controlled trial of sublingual immunotherapy in children with house dust mite allergy in primary care: study design and recruitment.	2008-10-20	18937864
Effectiveness of twice daily azelastine nasal spray in patients with seasonal allergic rhinitis.	2008-10	19209282
Contribution of alpha4beta1 integrin to the antiallergic effect of levocabastine.	2008-09-15	18680729
Treatment of allergic conjunctivitis with olopatadine hydrochloride eye drops.	2008-09	19668750
The effect of a combined therapy with a histamine H1 antagonist and a chemical mediator release inhibitor on allergic conjunctivitis.	2008	18463425
Neurotensin protects pancreatic beta cells from apoptosis.	2008	18456542
Clinical and biological efficacy of preservative-free NAAGA eye-drops versus levocabastine eye-drops in vernal keratoconjunctivitis patients.	2007-12	17585003
The effect of levocabastine and furosemide pretreatment on hyperreactive response after nasal provocation with hypotonic aerosol in subjects with allergic rhinitis.	2007-11	17618447
Inhibition of release of vasoactive and inflammatory mediators in airway and vascular tissues and macrophages by a chinese herbal medicine formula for allergic rhinitis.	2007-06	17549238
Seasonal allergic rhinitis in adolescents and adults.	2007-04-01	19454070
Review of azelastine nasal spray in the treatment of allergic and non-allergic rhinitis.	2007-04	17376024
Inhibition of release of inflammatory mediators in primary and cultured cells by a Chinese herbal medicine formula for allergic rhinitis.	2007-02-15	17302969
Interactions between NTS2 neurotensin and opioid receptors on two nociceptive responses assessed on the hot plate test in mice.	2006-12-15	17074405
Effect of antihistamine eye drops on the conjunctival provocation test with Japanese cedar pollen allergen.	2006-12	17130679
Effect of beta-lactotensin on acute stress and fear memory.	2006-12	17000030
The early efficacy of topical levocabastine in patients with allergic conjunctivitis.	2006-09	17075271
[Misleading advertisement on Opatanol].	2006-07-01	16875272
Effects of excitotoxic lesions of the medial prefrontal cortex on density of high affinity [125I-Tyr3]neurotensin binding sites within the ventral midbrain and striatum.	2006-06-13	16714012
Efficacy of levocabastine hydrochloride ophthalmic suspension in the conjunctival allergen challenge test in Japanese subjects with seasonal allergic conjunctivitis.	2006-06	17075252
Preferential inhibition of human phosphodiesterase 4 by ibudilast.	2006-05-01	16313925
The reliability, validity, and preliminary responsiveness of the Eye Allergy Patient Impact Questionnaire (EAPIQ).	2005-10-31	16259630
Potent spinal analgesia elicited through stimulation of NTS2 neurotensin receptors.	2005-09-07	16148226
Efficacy, cost-effectiveness, and tolerability of mometasone furoate, levocabastine, and disodium cromoglycate nasal sprays in the treatment of seasonal allergic rhinitis.	2005-09	16200819
[Comparison of three antiallergic eyedrops in a specific conjunctival provocation test: mequitazine, levocabastine and dexamethasone].	2005-03	15883488
Comparison of allergen immunotherapy and drug treatment in seasonal rhinoconjunctivitis: a 3-years study.	2005-02	15859367
Actual therapeutic management of allergic and hyperreactive nasal disorders.	2004	22073046
Stable expression of the mouse levocabastine-sensitive neurotensin receptor in HEK 293 cell line: binding properties, photoaffinity labeling, and internalization mechanism.	1998-02-13	9480852
Structure, functional expression, and cerebral localization of the levocabastine-sensitive neurotensin/neuromedin N receptor from mouse brain.	1996-09-15	8795617
Molecular cloning of a levocabastine-sensitive neurotensin binding site.	1996-05-20	8647296
Selective effect of levocabastine on histamine receptor and histamine release from human leukocytes and guinea pig isolated tissue.	1996-04	8612114
Evidence for a displaceable non-specific [3H]neurotensin binding site in rat brain.	1986-08	3022160

Patents

Sample Use Guides

In Vivo Use Guide

The usual dose is one drop instilled in affected eyes four times per day.

Route of Administration: Other

In Vitro Use Guide

Levocabastine binds the alpha(4)beta(1) integrin and prevents eosinophil adhesion to vascular cell adhesion molecule-1 (VCAM-1), FN or human umbilical vascular endothelial cells (HUVEC) in vitro

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:50:43 GMT 2025` Edited by `admin` on `Mon Mar 31 18:50:43 GMT 2025`
Record UNII	COU3RRH769
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

(±)-TRANS-1-(CIS-4-CYANO-4-(P-FLUOROPHENYL)CYCLOHEXYL)-3-METHYL-4-PHENYLISONIPECOTIC ACID

Preferred Name

English

CABASTINE

Official Name

English

cabastine [INN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C29578